A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Primary Tauopathies (clinicaltrials.gov) - Oct 9, 2026 - P2 | N=48 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals
New P2 trial • CNS Disorders • Frontotemporal Lobar Degeneration • Movement Disorders • Progressive Supranuclear Palsy • MAPT
|